| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 16
| Issue : 71 | Page : 574-579 |
|
|
Isoliquiritigenin induces apoptosis through caspases and reactive oxygen species signaling pathways in human bladder cancer cells
Minwoo Hwang1, Min Ji Kwon2, Byung Joo Kim2
1 Department of Sasang Constitutional Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Korea
2 Division of Longevity and Biofunctional Medicine, Healthy Aging Korean Medical Research Center, School of Korean Medicine, Pusan National University, Yangsan, Korea
Correspondence Address:
Byung Joo Kim
Division of Longevity and Biofunctional Medicine,
Healthy Aging Korean Medical Research Center, School of Korean Medicine, Pusan National University, Yangsan 50612
Korea
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/pm.pm_21_20
|
|
|
Background: Isoliquiritigenin (ISL) is a flavonoid isolated from the roots of various species of licorice plants. Objectives: Mechanisms underlying ISL-induced cell death were investigated in 5637 human bladder cancer cell line. Materials and Methods: Cell viabilities were measured with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide and cell counting kit-8 assay. Cell cycle analysis, caspase activity assay, western blotting, and reactive oxygen species (ROS) assay were also used to investigate the anticancer effects of ISL on 5637 cells. Results: ISL (100–500 μg/ml) inhibited cancer cell proliferation and increased sub-G1 cell cycle phase ratios. ISL-induced cell death resulted in reduced Bcl-2 and increased Bax. ISL also activated caspase-3 and -9 and increased the levels of intracellular ROS generated. In addition, TG100-115 (transient receptor potential [TRP] melastatin 7 inhibitor) and tranilast (TRP vanilloid 2 inhibitor) each exerted a synergistic effect with ISL on ISL-induced apoptosis. Conclusion: These findings suggest that ISL causes apoptosis in 5637 cancer cell line. Therefore, ISL may be a potential anticancer drug for treating bladder cancer and a good anticancer supplement.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
